摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[4-(methylsulfonyl)-butyl]cyclobutanecarboxylic acid ethyl ester | 288616-31-9

中文名称
——
中文别名
——
英文名称
1-[4-(methylsulfonyl)-butyl]cyclobutanecarboxylic acid ethyl ester
英文别名
1-[4-(Methylsulfonyl)butyl]cyclobutanecarboxylic acid ethyl ester;ethyl 1-(4-methylsulfonylbutyl)cyclobutane-1-carboxylate
1-[4-(methylsulfonyl)-butyl]cyclobutanecarboxylic acid ethyl ester化学式
CAS
288616-31-9
化学式
C12H22O4S
mdl
——
分子量
262.37
InChiKey
VOLKBKVSZSLNLR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    17
  • 可旋转键数:
    8
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.92
  • 拓扑面积:
    68.8
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    1-[4-(methylthio)butyl]cyclobutanecarboxylic acid ethyl ester 、 1-[4-(methylsulfonyl)-butyl]cyclobutanecarboxylic acid ethyl ester 生成 Ethyl 1-[4-(methylsulfonyl)butyl]cyclobutane carboxylic acid ethyl ester
    参考文献:
    名称:
    Heterocyclic thioamide derivatives
    摘要:
    已经发现了以下式子的化合物:1及其药用可接受的盐和酯,其中X和Y的定义如下,可以抑制VCAM-1与VLA-4的结合,并且有助于治疗与慢性炎症性疾病相关的炎症,例如类风湿性关节炎(RA),多发性硬化症(MS),哮喘和炎症性肠病(IBD)。
    公开号:
    US20020052508A1
点击查看最新优质反应信息

文献信息

  • Diephenyl carbocyclic thioamide derivatives
    申请人:——
    公开号:US20010041799A1
    公开(公告)日:2001-11-15
    It has been discovered that compounds of the formula: 1 and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, inhibit the binding of VCAM-1 to VLA-4 and are useful in treating inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, (MS), asthma, and inflammatory bowel disease (I BD).
    已发现以下化合物的公式:1及其药学上可接受的盐和酯,其中X和Y的定义如下,能够抑制VCAM-1与VLA-4的结合,并且适用于治疗与慢性炎症性疾病相关的炎症,例如类风湿性关节炎(RA),多发性硬化症(MS),哮喘和炎症性肠病(I BD)。
  • PHENYL-KETO-IMIDAZOLIDINE THIOAMIDE DERIVATIVES
    申请人:——
    公开号:US20020010338A1
    公开(公告)日:2002-01-24
    It has been discovered that compounds of the formula: 1 and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, inhibit the binding of VCAM-1 to VLA-4 and are useful in treating inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, (MS), asthma, and inflammatory bowel disease (I BD).
    已经发现了以下化合物的公式1及其药学上可接受的盐和酯,其中X和Y的定义如下,可以抑制VCAM-1与VLA-4的结合,并且在治疗与慢性炎症性疾病相关的炎症方面非常有用,如类风湿性关节炎(RA),多发性硬化症(MS),哮喘和炎症性肠病(IBD)。
  • Thioamide derivatives
    申请人:——
    公开号:US20020028933A1
    公开(公告)日:2002-03-07
    It has been discovered that compounds of the formula: 1 and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, inhibit the binding of VCAM-1 to VLA-4 and are useful in treating inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, (MS), asthma, and inflammatory bowel disease (I BD).
    已经发现了化学式为1的化合物及其药学上可接受的盐和酯,其中X和Y如下定义,可以抑制VCAM-1与VLA-4的结合,并且在治疗与慢性炎症性疾病相关的炎症方面具有用途,例如类风湿性关节炎(RA)、多发性硬化症(MS)、哮喘和炎症性肠病(I BD)。
  • Diphenyl heterocyclic thioamide derivatives
    申请人:——
    公开号:US20020040148A1
    公开(公告)日:2002-04-04
    It has been discovered that compounds of the formula: 1 and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, inhibit the binding of VCAM-1 to VLA-4 and are useful in treating inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, (MS), asthma, and inflammatory bowel disease (I BD).
    已经发现以下化合物的公式:1及其药学上可接受的盐和酯,其中X和Y的定义如下,可以抑制VCAM-1与VLA-4的结合,并且在治疗与慢性炎症性疾病相关的炎症方面非常有用,例如类风湿性关节炎(RA),多发性硬化症(MS),哮喘和炎症性肠病(I BD)。
  • Diphenyl carbocyclic thioamide derivatives
    申请人:Hoffmann-La Roche Inc.
    公开号:US06458844B2
    公开(公告)日:2002-10-01
    It has been discovered that compounds of the formula: and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, inhibit the binding of VCAM-1 to VLA-4 and are useful in treating inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, (MS), asthma, and inflammatory bowel disease (I BD).
    已经发现,公式为:其中X和Y的定义如下,以及其药学上可接受的盐和酯类化合物,可以抑制VCAM-1与VLA-4的结合,并且在治疗与慢性炎症性疾病相关的炎症方面非常有用,例如类风湿性关节炎(RA),多发性硬化症(MS),哮喘和炎症性肠病(I BD)。
查看更多